Andrew Combs Vice President at Incyte Corporation

Andrew Combs

Vice President at Incyte Corporation

LINKS

• https://www.linkedin.com/in/andrew-combs-4514413

  
  

  Summary

  Andrew P. Combs, Ph.D., joined Incyte in 2003 where he is currently Vice President of Discovery Chemistry. He has led medicinal chemistry programs in oncology and inflammation to >10 nomination candidates during his ~19 year tenor in the pharmaceutical industry. INCB024360 (Epacadostat) - an IDO1 inhibitor, INCB054329 - a BRD inhibitor, and INCB050465 - a PI3Kd inhibitor are currently being studied in human clinical trials for oncology. He is also responsible for the Discovery Analytical, Chemical Technologies, Chemical Informatics and the Computational Chemistry departments. Prior to Incyte, Dr. Combs was a Director at Bristol-Myers Squibb and Dupont-Merck where he led programs in the CNS area and founded a >50 member cross-functional target-directed Parallel Synthesis Team. Andrew’s research interests embrace the application of innovative technologies to expedite the drug discovery process, such as fragment-based approaches, structure-based drug design, parallel synthesis, microwave-assisted synthesis and automated LCMS purification methods. He has published >100 research articles/book chapters, been granted >30 patents, presented numerous invited lectures, served on editorial boards of three scientific journals (currently J. Med. Chem. Letters), co-chaired >10 ACS conferences, served on a variety of NIH review panels, and currently is a member of the SAB for Boston University CMD and the University of Delaware NIH-funded COBRE. Dr. Combs was a HHMI post-doctoral fellow in the laboratories of Prof. Stuart L. Schreiber at Harvard from 1994-1996 and holds a Ph.D. in Organic Chemistry from UCLA and BS degrees in Chemistry and Molecular Biology from the University of Wisconsin at Madison.

  Experience

  
  

  

  Vice President

  Incyte Corporation

  January 2003 – Present (13 years 4 months)
  

  Led medicinal chemistry team to the identification of the first-in-class immunotherapy drug, INCB024360 (Epacadostat), an inhibitor of indoleamine-dioxygenase-1 (IDO1). Non-exclusive collaborations with Merck, BMS, AZ and Genentech have been established to conduct Phase I/II oncology studies to evaluate the efficacy and safety of their respective anti-PD-L1 and anti-PD-1 immune checkpoint inhibitors, in combination with Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, Epacodostat.
  
  Led medicinal chemistry team to the identification of INCB050465 (PI3Kd inhibitor) and INCB054329 (BRD inhibitor) which are currently in Phase I oncology studies.

  
  

  

  Director

  Bristol Myers Squibb

  2002 – 2003 (1 year)
  

  Concurrently the working group chair for the CRF1 Project, head of the Parallel Synthesis Group, head of the Peptide Synthesis Group, and oversaw a collaboration with Albany Molecular Research Institute (AMRI).

  
  

  Director

  DuPont - DuPont/Merck Pharmaceuticals

  April 1996 – August 2002 (6 years 5 months)
  

  Initiated and led a Parallel Synthesis group that discovered novel inhibitors for a broad range of drug targets in CNS, oncology, cardiovascular, and anti-microbial indications. The team was also responsible for the development and dissemination of innovative technologies to the medicinal chemistry department, including of parallel synthesis, microwave synthesis and preparative LCMS technologies.

  
  

  Education

  
  

  

  Harvard University

  Post Doctoral, Chemical Biology

  1994 – 1996
  

  Advisor: Prof. Stuart Schreiber
  
  Howard Hughes Medical Institute (HHMI) Post doctoral fellow

  
  

  

  University of California, Los Angeles

  Ph.D., Organic Chemistry

  1989 – 1994
  

  Advisor: Prof. Robert Armstrong
  
  "Synthesis and Structure-Activity Relationship Analysis of Dehydroamino Acid Derivatives Related to the Azinomycins", Andrew P. Combs, Diss. Abstr. Int. B 1994, 55(11) 4850.

  
  

  

  University of Wisconsin-Madison

  Bachelor of Sciences (BS), Double Major - Chemistry and Molecular Biology

  1984 – 1988
  

  Advisor: Prof. Robert McMahon

TEAMWORK

Incyte’s team (from left): Andrew Combs, Dilip Modi, Joe Glenn, Brent Douty, Padmaja Polam, Brian Wayland, Rick Sparks, Wenyu Zhu, and Eddy Yue.

Credit: Incyte

1st row:  Jingmei Shen, Benjamin Israel, and Aparna Sapara;
2nd row:  Andrew Combs (Incyte Biopharmaceutical Company), Joseph Keane (Muhlenberg College), 
               Bob Opila (Materials Science, UD), Ya-Ming Hou (Jefferson University) and Derrick Swinton (Lincoln University)

///////

Dr. Jo Viney, Vice President, Immunology Research at Biogen

 
Dr. Jo Viney, Vice President, Immunology Research at Biogen



Dr. Jo Viney is Vice President, Immunology Research at Biogen in Cambridge, MA. In this role, Jo is responsible for setting scientific research direction and strategy with a focus on target identification and validation for drug discovery and development for treating patients with autoimmune and inflammatory diseases. Jo received her PhD from St Bartholomew’s Hospital, University of London in 1991 and pursued postdoctoral fellowships first at the Imperial cancer Research Fund in London, UK, and at Genentech in the Bay Area, California. Following her training, Jo joined Immunex in 1995 and remained at the company, which was acquired by Amgen in 2002, until leaving to join Biogen Idec. Jo has advanced a portfolio of novel biologic and small molecule programs, seven of which have progressed to IND and into clinical development, for diseases such rheumatoid arthritis, asthma, atopic dermatitis, psoriasis, inflammatory bowel disease and lupus. Jo has maintained longstanding membership with the American Society of Immunologists (AAI), the British Society for Immunology (BSI) and the Society for Mucosal Immunology (SMI). She served as President of SMI from 2011-2013. Together with her SMI colleagues, she launched the journal Mucosal Immunology with Nature Publishing Group in 2007. Jo has been a member of the Scientific Advisory Board for Keystone Symposia since 2008, and she partners with KS on a number of programs for under-represented scientists. She is also member of the Scientific Advisory Board for the BioAster Technology Research Institute (IRT) in France, and for Vaxart Inc in the Bay Area. 


 


 LINKS

• https://www.linkedin.com/in/jo-viney-8547b86

Experience

Senior Vice President, Drug Discovery

Biogen

October 2015 – Present (7 months)Cambridge, MA

Vice President, Immunology Research

Biogen Idec

July 2011 – September 2015 (4 years 3 months)Cambridge, MA

Executive Director, Inflammation Research

Amgen

July 2002 – May 2011 (8 years 11 months)

Inflammation Research

Staff Scientist, Autoimmunity and Inflammation Research

Immunex

October 1995 – July 2002 (6 years 10 months)Greater Seattle Area

Postdoc

Genentech

March 1994 – September 1995 (1 year 7 months)

Postdoc

Imperial Cancer Research Fund

November 1990 – February 1994 (3 years 4 months)

Education

St Bart's Hospital, University of London

PhD, Gut Immunology

1987 – 1990

University of East London

BSc, Biophysics

1983 – 1987

 .

Jo Viney

Vice President, Postdoc Mentor

Immunology

My particular area of interest revolves around understanding the mechanistic basis of immune homeostasis in organs susceptible to inflammatory disease. Past work has included investigating tolerogenic antigen presentation in the intestine, developing new mouse models of colitis and studying the function of novel butyrophilin-like (BTNL) inhibitory molecules.
I am the vice president of the immunology research group at Biogen. The group’s mission is to develop treatments for underserved immune-mediated inflammatory diseases associated with autoimmunity and fibrosis. Research extends from basic target identification and validation through to drug discovery and preclinical development.

Education

• Postdoc, Genentech, UK and USA, 1995
• Postdoc, Imperial Cancer Research Fund, UK, 1994
• Ph.D., St Bart’s Hospital, University of London, London, UK, 1991

• B.Sc., University of East London, London, UK, 1987

Selected Publications

• Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells.
  J Immunol. 2013 Mar 1;190(5):2027-35. doi: 10.4049/jimmunol.1201760. Epub 2013 Jan 28.
  Swanson RM, Gavin MA, Escobar SS, Rottman JB, Lipsky BP, Dube S, Li L, Bigler J, Wolfson M, Arnett HA, Viney JL.
  PMID: 23359506
• The tale of TL1A in inflammation.
  Mucosal Immunol. 2011 Jul;4(4):368-70. doi: 10.1038/mi.2011.20. Epub 2011 May 4. Review.
  Hsu H, Viney JL.
  PMID: 21544073
• Gatekeepers of intestinal inflammation.
  Inflamm Res. 2010 Jan;59(1):1-14. Review.
  Arnett HA, Viney JL.
  PMID: 20066780
• Recent developments in IBD and the B7 family of costimulatory molecules.
  Curr Opin Investig Drugs. 2009 May;10(5):443-51. Review.
  Arnett HA, Viney JL.
  PMID: 19431077
• Regulation of costimulation in the era of butyrophilins.
  Cytokine. 2009 Jun;46(3):370-5. doi: 10.1016/j.cyto.2009.03.009. Epub 2009 Apr 19. Review.
  Arnett HA, Escobar SS, Viney JL.
  PMID: 19380239
• BTNL2, a butyrophilin/B7-like molecule, is a negative costimulatory molecule modulated in intestinal inflammation.
  J Immunol. 2007 Feb 1;178(3):1523-33.
  Arnett HA, Escobar SS, Gonzalez-Suarez E, Budelsky AL, Steffen LA, Boiani N, Zhang M, Siu G, Brewer AW, Viney JL.
  PMID: 17237401
• From model to mechanism: lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease.
  Expert Opin Drug Discov. 2006 Jun;1(1):69-83. doi: 10.1517/17460441.1.1.69.
  Bilsborough J, Viney JL.
  PMID: 23506033
• Mouse models of inflammatory bowel disease.
  Curr Opin Drug Discov Devel. 2006 Mar;9(2):207-17. Review.
  Byrne FR, Viney JL.
  PMID: 16566291
• Dual infection with Helicobacter bilis and Helicobacter hepaticus in p-glycoprotein-deficient mdr1a-/- mice results in colitis that progresses to dysplasia.
  Am J Pathol. 2005 Jun;166(6):1793-806.
  Maggio-Price L, Bielefeldt-Ohmann H, Treuting P, Iritani BM, Zeng W, Nicks A, Tsang M, Shows D, Morrissey P, Viney JL.
  PMID: 15920164
• The mdr1a-/- mouse model of spontaneous colitis: a relevant and appropriate animal model to study inflammatory bowel disease.
  Immunol Res. 2005;31(2):151-9. Review.
  Wilk JN, Bilsborough J, Viney JL.
  PMID: 15778512
• Out, out darn toxin: the role of MDR in intestinal homeostasis.
  Gastroenterology. 2004 Jul;127(1):339-40. Review. No abstract available.
  Bilsborough J, Viney JL.
  PMID: 15236205
• Gastrointestinal dendritic cells play a role in immunity, tolerance, and disease.
  Gastroenterology. 2004 Jul;127(1):300-9. Review.
  Bilsborough J, Viney JL.
  PMID: 15236195
• Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties.
  Immunology. 2003 Apr;108(4):481-92.
  Bilsborough J, George TC, Norment A, Viney JL.
  PMID: 12667210
• GM-CSF treatment for Crohn's disease: a stimulating new therapy?
  Curr Opin Investig Drugs. 2002 Sep;3(9):1291-6. Review.
  Wilk JN, Viney JL.
  PMID: 12498002
• Regulation of mucosal dendritic cell function by receptor activator of NF-kappa B (RANK)/RANK ligand interactions: impact on tolerance induction.
  J Immunol. 2002 Oct 1;169(7):3606-12.
  Williamson E, Bilsborough JM, Viney JL.
  PMID: 12244151
• Getting to the guts of immune regulation.
  Immunology. 2002 Jun;106(2):139-43. Review. No abstract available.
  Bilsborough J, Viney JL.
  PMID: 12047743
• Interleukin 18 is a primary mediator of the inflammation associated with dextran sulphate sodium induced colitis: blocking interleukin 18 attenuates intestinal damage.
  Gut. 2002 Jun;50(6):812-20.
  Sivakumar PV, Westrich GM, Kanaly S, Garka K, Born TL, Derry JM, Viney JL.
  PMID: 12010883
• Helicobacter bilis infection accelerates and H. hepaticus infection delays the development of colitis in multiple drug resistance-deficient (mdr1a-/-) mice.
  Am J Pathol. 2002 Feb;160(2):739-51.
  Maggio-Price L, Shows D, Waggie K, Burich A, Zeng W, Escobar S, Morrissey P, Viney JL.
  PMID: 11839595
• Immune fate decided by dendritic cell provocateurs.
  Trends Immunol. 2001 Jan;22(1):8-10. No abstract available.
  Viney JL.
  PMID: 11334031
• The ins and outs of body surface immunology.
  Science. 2000 Oct 6;290(5489):97-100. Review.
  Hayday A, Viney JL.
  PMID: 11021807 

////////////

Wendy Young, Vice President, Discovery Chemistry at Genentech

Wendy Young

Vice President, Discovery Chemistry at Genentech

Ensuring that we have a culture that supports innovation and provides access to the most cutting edge approaches and tools is key. Just as important is that we continue to recruit and retain the brightest chemists on the planet.

LINKS

https://www.linkedin.com/pub/wendy-young/2/157/65a

Wendy B. Young,

young.wendy@gene.com

Genentech Inc. 1 DNA Way MS#18 South San Francisco, CA 94080 Phone: 650-467-7945 young.wendy@gene.com\

Wendy Young, Ph.D., Director, Discovery Chemistry, Genentech

Wendy B. Young has nineteen years of industrial drug discovery experience, having led discovery efforts at both small biotech firms (Axys/Celera and Scios: 1995-2006) and larger companies (Genentech/Roche: 2006-present). Wendy is currently Director of Medicinal Chemistry at Genentech, where she is a leader of project teams and directs a large group of medicinal chemists.

These teams have produced multiple clinical candidates, from a variety of target classes, currently under clinical evaluation in a range of indications.

She was recently elected as Vice Chair of the ACS Medicinal Chemistry (ACS MEDI) Division which will culminate in her being Chair of the Division in 2017.

Wendy received her Ph.D. from Princeton University under the direction of E.C. Taylor and carried out Postdoctoral Studies at Memorial Sloan Kettering Cancer Center with Professor Samuel Danishefsky.

Wendy is listed as an inventor or author on over 65 patent and research publications and has given presentations at many national and international meetings.

http://www.gene.com/scientists/our-scientists/wendy-young

"We all know friends and family members that have suffered with serious illness. It can be devastating. My goal, alongside my colleagues, is to discover agents that will treat these patients. The motto "patients are waiting" really hits home with everyone."

I was drawn to join Genentech, in 2006, because of its reputation for doing excellent science and employing strong teamwork. At Genentech, any team member with a compelling idea gets a chance to be heard and access to the resources to move their idea forward. The organization is also very nimble and open-minded to incorporate processes to accelerate discovery and development. Today, I am Vice President of Discovery Chemistry, overseeing a highly talented and experienced group of medicinal, computational and analytical chemists. These Genentech chemists are integral on our project teams to innovate and discover the next generation of medicines to treat patients in need. What excites me the most is that, at Genentech, we have the brightest people, tools, and know-how to continue to make huge strides in solving complex biological and medical issues. It is a huge opportunity and responsibility to shape the future treatments for patients in need.

FEATURED PUBLICATION

Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nature Chemical Biology, 2011, ISSN: 1552-4469 Di Paolo, J.; Huangm T.; Balazs, M.; Barbosa, J.; Barck, K.; Bravo, B.;Carano, R.; Darrow, J.; Davies, D.; DeForge, L.; Diehl, L.; Ferrando,R.; Gallion, S.; Giannetti, A.; Gribling, P.; Hurez, V.; Hymowitz, S.; Jones, R.; Kropf, J.; Lee, W.; Maciejewski, P.; Mitchell, S.; Rong, H.; Staker, B.; Whitney, A.; Yeh, S.; Young, W.; Yu, C.; Zhang, J.; Reif,K.; Currie, K. View Abstract on PubMed

Experience

Vice President, Discovery Chemistry

Genentech

January 2015 – Present (10 months)

Senior Director, Discovery Chemistry

Genentech

October 2014 – Present (1 year 1 month)

Director, Discovery Chemistry

Genentech

November 2012 – Present (3 years)

Associate Director, Medicinal Chemistry

Genentech, Inc.

October 2006 – 2012 (6 years)

Associate Director, Medicinal Chemistry

Scios, a Johnson & Johnson Co.

January 2006 – October 2006 (10 months)

Senior Director, Medicinal Chemistry

Celera

1995 – 2006 (11 years)

Postdoctoral Fellow

Sloan-Kettering Cancer Center

1993 – 1995 (2 years)

Advisor: Samuel Danishefsky Design and total synthesis of the anti-cancer agent Taxol®

Education

Princeton University

PhD, Chemistry

1988 – 1993

Advisor: E.C. Taylor Dissertation: Design and Synthesis of Folate Analogs as Novel Anti-Cancer Agents

Wake Forest University

BA, MS, Chemistry

1984 – 1989

Advisor: Huw M.L. Davies: Thesis: Novel Entry into the Tropane Alkyloid Ring System Via Reactions of Vinyl Carbenoids and Pyrroles"

• Sloan Kettering Cancer Center, American Cancer Society, Postdoctoral Fellow – 1995
• Princeton University, Ph.D. Chemistry – 1993
• Wake Forest University, B.A./M.S. Chemistry, cum laude – 1988
• AWARDS
• • Elected Chair of National ACS MEDI – 2017
  • Elected Program Chair of National ACS MEDI – 2015-2016
  • Elected Vice Chair of National ACS MEDI – 2014
  • American Cancer Society Postdoctoral Fellowship – 1993-1995
  • H. W. Dodds - Princeton University Honorific Fellowship, Top Thesis Award – 1993
  • Josephine de Karman Fellowship – 1992
  • ACS Graduate Fellowship sponsored by Lilly Research Laboratories – 1991-1992
  • Department of Education Graduate Fellowship – 1990
  • BA/MS Chemistry Scholarship, Wake Forest University – 1988

• Potent and selective Bruton's tyrosine kinase inhibitors: Discovery of GDC-0834

  Bioorganic & medicinal chemistry letters, 2015, ISSN: 0960-894X
  Young, Wendy B; Barbosa, James; Blomgren, Peter; Bremer, Meire C; Crawford, James J; Dambach, Donna; Gallion, Steve; Hymowitz, Sarah G; Kropf, Jeffrey E; Lee, Seung H; Liu, Lichuan; Lubach, Joseph W; Macaluso, Jen; Maciejewski, Pat; Maurer, Brigitte; Mitchell, Scott A; Ortwine, Daniel F; Di Paolo, Julie; Reif, Karin; Scheerens, Heleen; Schmitt, Aaron; Sowell, C Gregory; Wang, Xiaojing; Wong, Harvey; Xiong, Jin-Ming; Xu, Jianjun; Zhao, Zhongdong; Currie, Kevin S
  View on PubMed

• 3-Heterocyclyl quinolone inhibitors of the HCV NS5B polymerase

  Bioorganic and Medicinal Chemistry Letters, 1 January 2012, v22, p300-304, ISSN: 0960-894X.
  Kumar, Dange V.; Rai, Roopa; Brameld, Ken A.; Ton, Tony L.; Riggs, Jennifer; Somoza, John R.; Rajagopalan, Ravi; Janc, James W.; Xia, Yu M.; Hu, Huiyong; Young, Wendy B.; Lehoux, Isabelle; Ho, Joseph D.; Hart, Barry; Green, Michael J.
  View on PubMed

• Significant Species Difference in Amide Hydrolysis of GDC-0834, a Novel Potent and Selective Bruton's Tyrosine Kinase (BTK) Inhibitor

  Drug metabolism and disposition: the biological fate of chemicals, {Drug-Metab-Dispos}, 8 Jul 2011 (epub: 8 7 2011), ISSN: 1521-009X.
  Liu, Lichuan; Halladay, Jason; Shin, Young; Wong, Susan; Coraggio, Melis; La, Hank; Baumgardner, Matthew; Le, Hoa; Gopaul, Sashi; Boggs, Jason; Kuebler, Peter; Davis, John; Liao, Charlene; Lubach, Joseph; Deese, Alan; Sowell, Gregory; Currie, Kevin; Young, Wendy; Khojasteh, Cyrus; Hop, Cornelis; Wong, Harvey
  View on PubMed

• Pyrazolopyridine Inhibitors of B-Raf^V600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors.

  ACS Medicinal Chemistry Letters, 2011, ISSN: 1948-5875
  Wenglowsky, Steve; Ren, Li; Ahrendt, Kateri; Laird, Ellen; Aliagas, Ignacio; Alicke, Bruno; Buckmelter, Alex; Choo, Edna; Dinkel, Victoria; Feng, Bainian; Gloor, Susan; Gould, Stephen; Gross, Stefan; Gunzner-Toste, Janet; Hansen, Joshua; Hatzivassiliou, Georgia; Liu, Bonnie; Malesky, Kim; Mathieu, Simon; Newhouse, Brad; Raddatz, Nicholas; Ran, Yingqing; Rana, Sumeet; Randolph, Nikole; Risom, Tyler; Rudolph. Joachim; Savage, Scott; Selby, LeAnn; Shrag, Michael; Song, Kyung; Sturgis, Hillary; Voegtli, Walter; Wen, Zhaoyang; Willis, Brandon; Woessner, Richard; Wu, Wen-I; Young, Wendy; Grina, Jonas
  View on PubMed

• Quinolones as HCV NS5B Polymerase Inhibitors

  Bioorganic & Medicinal Chemistry Letters, 2011,
  Kumar, Dange; Rai, Roopa; Brameld, Ken; Somoza, John; Rajagopalan, Ravi; Janc, James; Xia, Yu; Ton, Tony; Shaghafi, Michael; Hu, Huiyong; Lehoux, Isabelle; To, Nhat; Young, Wendy; Green, Michael;
  View on PubMed

• Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis

  Nature Chemical Biology, 2010, ISSN: 1552-4469
  Di Paolo, Julie; Huang, Tao; Balazs, Mercedesz; Barbosa, James; Barck, Kai; Bravo, Brandon; Carano, Richard; Darrow, James; Davies, Douglas; DeForge, Laura; Diehl, Lauri; Ferrando, Ronald; Gallion, Steven; Giannetti, Anthony; Gribling, Peter; Hurez, Vincent; Hymowitz, Sarah; Jones, Randall; Kropf, Jeffrey; Lee, Wyne; Maciejewski, Patricia; Mitchell, Scott; Rong, Hong; Staker, Bart; Whitney, Andrew; Yeh, Sherry; Young, Wendy; Yu, Christine; Zhang, Juan; Reif, Karin; Currie, Kevin
  View on PubMed

CLIPS.........

Influential Women 2015: Wendy Young

Wendy Young, Ph.D.

Vice president, discovery chemistry, Genentech

Influential Women 2015

Education: B.A., M.S., chemistry, Wake Forest University; Ph.D., chemistry, Princeton University.

Proudest professional accomplishment: I was team leader for seven years on an important drug development project where there’s a lot of industry competition. We had to overcome many obstacles but I believed in the project and in the science and wouldn’t give up. We ultimately discovered the root of the problem and presented the data to regulators, and they allowed us to move the medicine into the clinic. Our team emerged as a really tight-knit group because we wouldn’t give up as we had a strong passion for the end goal. It was a great example of how perseverance is key.

Best mentor: One of my biggest role models is Michael Varney, executive vice president and head of research and early development at Genentech.

How to help women in business advance: What I’ve learned is that to succeed, you must have achievement. You’ll get more visibility by racking up achievements. Don’t be distracted by sideline activities because it takes away time and energy from things that will really matter. Be brave. Speak up. Figure out how to find your voice.

Dream super power: To not need sleep.

Surprising fact about you: I love to hula hoop!

http://berkeleysciencereview.com/piper-promotes-isp-seminar-with-dr-wendy-young-genentech/

Iota Sigma Pi - Hydrogen Chapter

September 19, 2012 ·

  
 
 
Dr. Wendy Young. — at College Of Chemistry - UC Berkeley.

.................................................................................

Executive Committee

Regular Executive Committee Members

Program Chair 2015-2016

Wendy B. Young, Ph.D. Vice President, Discovery Chemistry Genentech Inc. 1 DNA Way MS#18 South San Francisco, CA 94080 Phone: 650-467-7945 young.wendy@gene.com ..................................................................................
 

MEDICINAL & BIOLOGICAL CHEMISTRY

https://www.utoledo.edu/pharmacy/depts/mbc/MAGSS/keynote.html

Guest Speaker and Panelist

Dr. Wendy Young, Director of Medicinal Chemistry, Genentech; Vice Chair, ACS Medicinal Chemistry Division

Wendy B. Young has twenty years of drug discovery experience, having led discovery efforts at both small biotech firms (Axys/Celera and Scios: 1995-2006) and larger companies (Genentech/Roche: 2006-present). Wendy is currently Director of Medicinal Chemistry at Genentech, where she is a leader of project teams and directs a large group of medicinal chemists. These teams have produced multiple clinical candidates, from a variety of target classes, currently under clinical evaluation in a range of indications. Wendy received her Ph.D. from Princeton University in chemistry under the direction of E.C. Taylor and was an American Cancer Society Postdoctoral Fellow at Memorial Sloan Kettering Cancer Center with Professor Samuel Danishefsky. Wendy is listed as an inventor or author on over 65 patent and research publications and has given presentations at many national and international meetings. Wendy was recently elected as Vice Chair of the ACS Medicinal Chemistry (ACS MEDI) Division which will culminate in her being Chair of the Division in 2017.

Discovery and SAR of new Btk inhibitors that bind to the Btk ATP-binding cleft.

FromSpecific Btk inhibition suppresses B cell– and myeloid cell–mediated arthritis

• Wendy B Young,
• Show fewer authors

Nature Chemical Biology,7,41–50(2011)

doi:10.1038/nchembio.481

(a) Library design and identification of CGI560 (1). (b) Structure of CGI1746 (2) and SAR for H3 binding. The amide motif and t-butylphenyl group are required for potent Btk inhibition. IC₅₀s were determined at the K_m for Btk and are the mean ± s.e.m. of at least three experiments. (c) Kinome binding map of CGI1746 based on an Ambit screen, data provided in Supplementary Table 2. CGI1746 only showed significant binding to Btk at 1 μM, indicated by the red circle.

.............................................

Project Details:

Highlights in Medicinal Chemistry - Short Course to postgraduate students of the summer school at the Federal University of Rio de Janeiro (UFRJ)

Project No.:	2014-022-1-700
Start date:	2014-09-01
End date:	0000-00-00
Division:	Chemistry and Human Health Division

 The group during the Rio Summer School in Medicinal Chemistry (January 24-30, 2015); from left: A. Ganesan, Jan Heeres, Klaus Wanner, Joerg Senn-Bilfinger, Patrick Woster, Lidia M. Lima, Peter Bernstein, Eliezer J. Barreiro, Janos Fischer, Helmut Buschmann, Wendy Young, Tom Perun, and Carlos A.M. Fraga.
..........................................................

NOS 2015 Symposium University of Pennsylvania, 215-898-3048

NationalOrganicSymposium.org

https://www.organicdivision.org/ama/orig/NOS/speakers.html

June 28-July 2, 2015

44th NATIONAL ORGANIC CHEMISTRY SYMPOSIUM

Wendy Young Genentech

9th Annual Drug Discovery Chemistry from MDConferenceFinder.com

...............
  https://www.google.com.ar/patents/WO2010056875A1?cl=en

//////////Wendy Young, Vice President, Discovery Chemistry, Genentech